GCG and type 2 diabetes mellitus: Clinically licensed nitroglycerin patches allowed for the on-demand and sustained expression of glucagon-like peptide-1 by human cells engineered with a nitroglycerin-responsive gene switch subcutaneously implanted in mice with type 2 diabetes.